Biotechnology company developing targeted therapies for cancer.
Acrivon Therapeutics, Inc., based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company specializing in the development of precision oncology medicines. The company employs its innovative proteomics-based platform, Acrivon Predictive Precision Proteomics (AP3), to match patients with tumors predicted to be responsive to specific treatments. This approach includes the creation of proprietary OncoSignature companion diagnostics tailored to identify patients likely to benefit from Acrivon's drug candidates.
At the forefront of Acrivon's pipeline is ACR-368, its lead clinical candidate. ACR-368 is a selective small molecule inhibitor targeting CHK1 and CHK2, currently undergoing a potentially registrational Phase 2 trial across various tumor types. This initiative underscores Acrivon's commitment to advancing therapies that target critical nodes in DNA Damage Response and cell cycle regulation pathways, including promising preclinical stage programs such as WEE1 and PKMYT1.
Founded in 2018, Acrivon Therapeutics has rapidly established itself as a pivotal player in oncology research. By leveraging cutting-edge technologies and a patient-centric approach, the company aims to deliver transformative treatments for cancer patients worldwide. Acrivon continues to expand its scientific expertise and therapeutic portfolio, positioning itself at the forefront of precision medicine innovation in the biopharmaceutical industry.
With a dedicated focus on advancing novel therapies through rigorous clinical trials and strategic partnerships, Acrivon Therapeutics remains committed to addressing significant unmet needs in oncology. The company's headquarters in Massachusetts serves as a hub for pioneering research and development efforts aimed at improving outcomes and quality of life for patients battling cancer.